5-Lipoxygenase Inhibition as a Therapy to Prevent Cryptococcus-related IRIS
5-Lipoxygenase Inhibition as a Therapy to Prevent Cryptococcus-related IRIS
批准号:
10256128
负责人:
Floyd L. Wormley
金额:
$17.02万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-02-22 至 2023-01-31
关键词:
Acquired Immunodeficiency SyndromeAdrenal Cortex HormonesAnti-Inflammatory AgentsAntifungal AgentsAntifungal TherapyArachidonate 5-LipoxygenaseCCL2 geneCCL3 geneCessation of lifeComplicationCryptococcosisCryptococcusDataDeteriorationDevelopmentDiagnosisDiseaseEncephalitisExhibitsHIVHIV SeropositivityHumanImmune responseImmunityIndividualInfectionInfiltrationInflammatoryInflammatory ResponseKnock-outKnockout MiceLaboratoriesLeadLeukocyte TraffickingLungLymphocyteMeningoencephalitisModelingMorbidity - disease rateMyeloid CellsNeurologicNon-Steroidal Anti-Inflammatory AgentsPatientsPharmaceutical PreparationsPlacebosProductionRag1 MouseSignal TransductionSterilityStructure of parenchyma of lungSyndromeT cell therapyT-LymphocyteTestingTherapeuticVirusWild Type Mouseantiretroviral therapybrain tissuechemokineclinically relevantcytokineimmune reconstitutioninhibitor/antagonistmortalitymouse modelpathogenpreventprophylactic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Cryptococcal meningoencephalitis (CM) is the most common disseminated fungal disease in
AIDS patients and is responsible for 15% of AIDS-related deaths globally. A complication
associated with the initiation of antiretroviral therapy (ART) in HIV positive patients with CM is the
development of immune reconstitution inflammatory syndrome (IRIS) which can lead to severe
neurological sequela, morbidity, and significant mortality. IRIS afflicts up to 30% of HIV positive
patients with a prior diagnosis of cryptococcosis who begin ART. Current efforts to mitigate
Cryptococcus-related IRIS (C-IRIS) include delaying initiation of ART until sterile immunity is
achieved, and/or using corticosteroid and/or non-steroidal anti-inflammatory drugs (NSAIDs) as
anti-inflammatory agents to prevent C-IRIS. Significant drawbacks to these efforts are that
delaying ART therapy in HIV positive patients allows the virus to propagate unchecked and anti-
inflammatory drugs can inhibit host immune responses and potentially reduce anti-cryptococcal
drug activity. Thus, therapies that allow for ART initiation at the onset of diagnosis, do not inhibit
the efficacy of antifungal drugs or protective anti-cryptococcal host responses, and prevent
deleterious inflammatory responses will have a significant impact towards reducing morbidity
associated with C-IRIS. Preliminary studies in our laboratory show that inhibition of 5-
lipoxygenase (5-LO) activity results in a significant reduction in the neurological deterioration,
morbidity and mortality associated with CM. Specifically, studies using an experimental mouse
model of cryptococcosis show that 5-LO knockout (KO) mice, in contrast to wild-type (WT) mice,
do not exhibit the classic neurological sequela or mortality associated with CM. Moreover,
myeloid cell infiltration and the production of chemokines associated with the development of C-
IRIS in humans (i.e., CCL2 and CCL3) were significantly reduced in brain tissues of 5-LO KO
mice compared to WT mice. Taken together, these results lead us to hypothesize that inhibition
of 5-LO signaling reduces the neurological inflammatory sequelae leading to the
development of C-IRIS. To test our hypothesis, we propose to: 1) determine the impact of 5-
LO blockade on the development of C-IRIS and 2) demonstrate the therapeutic impact of 5-LO
inhibitors as an adjunct to antifungal therapy using a murine model of C-IRIS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
5-Lipoxygenase Inhibition as a Therapy to Prevent Cryptococcus-related IRIS
-
批准号:10358634
-
项目类别:
-
资助金额:$14.58万
-
财政年份:2021
-
负责人:Floyd L. Wormley
-
依托单位:
Induction of Protection Against Cryptococcus neoformans in Immune Deficient Hosts
-
批准号:8499245
-
项目类别:
-
资助金额:$17.27万
-
财政年份:2012
-
负责人:Floyd L. Wormley
-
依托单位:
Induction of Protection Against Cryptococcus neoformans in Immune Deficient Hosts
-
批准号:8414616
-
项目类别:
-
资助金额:$22.05万
-
财政年份:2012
-
负责人:Floyd L. Wormley
-
依托单位:
Identification of C. neoformans proteins that induce protective immunity.
-
批准号:7990317
-
项目类别:
-
资助金额:$21.68万
-
财政年份:2010
-
负责人:Floyd L. Wormley
-
依托单位:
Identification of C. neoformans proteins that induce protective immunity.
-
批准号:8067135
-
项目类别:
-
资助金额:$17.88万
-
财政年份:2010
-
负责人:Floyd L. Wormley
-
依托单位:
Protective Host Immunity Against Pulmonary Cryptoccoccosis
-
批准号:7775100
-
项目类别:
-
资助金额:$34.36万
-
财政年份:2007
-
负责人:Floyd L. Wormley
-
依托单位:
Protective Host Immunity Against Pulmonary Cryptococcosis
-
批准号:9214307
-
项目类别:
-
资助金额:$40.85万
-
财政年份:2007
-
负责人:Floyd L. Wormley
-
依托单位:
Protective Host Immunity Against Pulmonary Cryptoccoccosis
-
批准号:8019452
-
项目类别:
-
资助金额:$34.01万
-
财政年份:2007
-
负责人:Floyd L. Wormley
-
依托单位:
Protective Host Immunity Against Pulmonary Cryptoccoccosis
-
批准号:7365221
-
项目类别:
-
资助金额:$34.7万
-
财政年份:2007
-
负责人:Floyd L. Wormley
-
依托单位:
Protective Host Immunity Against Pulmonary Cryptoccoccosis
-
批准号:7587322
-
项目类别:
-
资助金额:$34.7万
-
财政年份:2007
-
负责人:Floyd L. Wormley
-
依托单位:
Protective Host Immunity Against Pulmonary Cryptococcosis
-
批准号:8752693
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2007
-
负责人:Floyd L. Wormley
-
依托单位: